Needle-based Percutaneous Ablation of Liver Tumors.

The goal of this clinical trial is to learn if INT001 can ablate liver tumors in adults in an outpatient setting. It will also help us learn about the safety of INT001. The main questions it aims to answer are: 1. Using a needle under image guidance, the liver tumor is accessed and INT001 is injected. Upon injection into tumor, does INT001 ablate/kill the tumor entirely? 2. What medical problems do participants experience when receiving INT001? Participants will: Receive INT001 on day 1. Visit the clinic day 7, 30 and 90. Receive lab tests during each visit and MRI on day 30 and 90.

Trial Details

NCT ID
NCT06689670
Phase
NA
Sponsor
inTumo Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Needle based delivery of INT001 into liver tumors under real-time image guidance
Locations (sample)
  • Topkapı, Istanbul, Turkey (Türkiye)|41.01857,28.93219

Key Eligibility Criteria

  • Diagnosis of primary or secondary liver cancer.
  • ECOG Performance Status score of 0 - 2
  • Age ≥18 years, \<100 years
  • Life expectancy of ≥3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →